NCT04637282: An ongoing trial by Polaryx Therapeutics, Inc.
This trial is ongoing. It must report results 1 year, 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04637282 |
|---|---|
| Title | A Randomized. Multicenter, Double-Blind, Placebo-Controlled Safety, Tolerability, and Efficacy Study of PLX-200 in Participants With Mild-to-Moderate Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 1, 2026 |
| Completion date | March 31, 2026 |
| Required reporting date | March 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |